Exscientia Q1 2024 Earnings Report Earnings HistoryForecast Exscientia EPS ResultsActual EPS-$0.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AExscientia Revenue ResultsActual Revenue$6.70 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AExscientia Announcement DetailsQuarterQ1 2024Date5/21/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseEXAI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Exscientia Earnings HeadlinesExscientia and Recursion Merge to Revolutionize Drug DiscoveryNovember 21, 2024 | markets.businessinsider.comRecursion, Exscientia officially combine to advance drug discoveryNovember 21, 2024 | markets.businessinsider.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 1, 2025 | Brownstone Research (Ad)Recursion: No News Isn't Good News When It Comes To Vanilla PipelineNovember 20, 2024 | seekingalpha.comBarclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)November 15, 2024 | markets.businessinsider.comRecursion and Exscientia Merger Approved by ShareholdersNovember 14, 2024 | markets.businessinsider.comSee More Exscientia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exscientia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exscientia and other key companies, straight to your email. Email Address About ExscientiaExscientia (NASDAQ:EXAI), an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.View Exscientia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
